Abstract:BACKGROUND: Fibrosing interstitial lung disease (ILD) encompasses more than 200 diverse pulmonary disorders, of which up to 40% become progressive. The 4 underlying ILD types most likely to result in progression are unclassified ILD/idiopathic interstitial pneumonia (IIP), autoimmune ILDs, exposure-related ILD/hypersensitivity pneumonitis, and sarcoidosis.OBJECTIVE: To compare health care resource utilization (HCRU) and costs among patients with fibrosing ILD that has progressed ("progressive" fibrosing cohort) vs patients whose fibrosis did not meet criteria set for progression ("not yet progressed" cohort).METHODS: This was a noninterventional study of commercial enrollees and Medicare Advantage with Part D beneficiaries, which used administrative claims data for the period from October 1, 2015, through May 31, 2021. Adult patients (aged ≥18 years) with fibrosing ILD and 12 months of continuous health plan enrollment were included. Patients with idiopathic pulmonary fibrosis, baseline ILD diagnoses, or missing demographic data were excluded. Patients were first classified according to the underlying type of fibrosing ILD. For statistical analyses of outcomes, 2 cohorts were compared within each subtype: progressive fibrosing ILD vs not yet progressed ILD. The final study population included propensity score-matched (PSM) patients (1:1) based on pre-ILD baseline demographic and clinical characteristics. HCRU categories included inpatient hospitalization counts and the number of inpatient days and total costs (in 2021 US dollars), analyzed descriptively and weighted by the per-patient-per-month cost. Lin's regression was used to predict 12-month total cost estimates for comparison by cohort.RESULTS: The distribution by underlying conditions was as follows: autoimmune ILD (n = 4,156), HP (n = 8,181), sarcoidosis (n = 775), and unclassified ILD/IIP (n = 18,635). After PSM, pre-ILD baseline variables were generally well balanced between the progressive and not yet progressed fibrosing ILD cohorts. For all underlying subtypes of ILD, patients in the progressive cohort had significantly more utilization and higher costs compared with patients in the not yet progressed cohort. Progressive cohorts had significantly higher adjusted rates of inpatient days among patients with at least 1 inpatient stay compared with the not yet progressed cohorts (all <i>P</i> < 0.01). In addition, the progressive cohorts had significantly higher adjusted 12-month total costs, with the differences ranging from $24,493 to $55,072 (all comparisons <i>P</i> < 0.001).CONCLUSIONS: Irrespective of underlying ILD type, patients with progressive fibrosing ILD had significantly increased HCRU and cost relative to those whose fibrosing ILD had not yet progressed.

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases

Progression of fibrosing interstitial lung disease

Fibrosing interstitial lung diseases: knowns and unknowns

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)

Diagnosis and Management of Fibrotic Interstitial Lung Diseases

The natural history of progressive fibrosing interstitial lung diseases

Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease

Progressive pulmonary fibrosis: an expert group consensus statement

Predicting progressive phenotype in patients with fibrotic interstitial lung disease

Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type

Progressive pulmonary fibrosis (PPF): Estimation of incidence and treatment rates in Japan using a claims database

Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease

Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts

Treatment patterns and patient journey in progressive pulmonary fibrosis: a cross-sectional survey

Idiopathic Pulmonary Fibrosis in the United Kingdom: Findings from the first decade of the largest single-country IPF Registry

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)

Focus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis, and Treatment

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views

Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline